Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

The New York Times – Business:

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

This post first appeared in The New York Times – Business. Read the original article.